High-grade gliomas may be able to wire themselves into the healthy brain, receiving and interpreting electrical signals from normal neurons.
This week in industry includes trials on elenbecestat to be discontinued, ofatumumab demonstrating superiority to Aubagio and the Toca 5 trial results failing to meet primary endpoint.
In a large data study, researchers discover that terazosin, a drug typically used to treat enlarged prostate, might be able to slow down neurodegeneration in Parkinson’s disease.
In this interview from the Video Journal of Biomedicine, Hannah Brown (Ipsos Healthcare, London, UK) discusses physician and patient treatment decision-making for relapsing–remitting multiple sclerosis.
Take a look behind the scenes of a study published in Brain, as we ask Dr Ryan D’Arcy about the establishment of brain vital signs for concussion-related impairments.
Discover more about an ongoing, multicenter registry that provides real-world evidence regarding ataluren use in nonsense mutation Duchenne muscular dystrophy patients in this research article.